Report cover image

Retinal Vein Occlusion: Market View

Publisher GlobalData
Published Oct 31, 2025
Length 114 Pages
SKU # GBDT20939873

Description

Retinal Vein Occlusion: Market View

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Retinal Vein Occlusion Therapeutics.
  • In 2024 and 2029, China is anticipated to have the highest number of diagnosed prevalent cases of BRVO, representing a large portion of global cases.
  • Currently, the RVO market lacks disease-modifying therapies, as no cure can reverse the blockage itself. Current treatments focus on managing complications like macular edema and neovascularization to stabilize vision and prevent further loss.
  • The RVO pipeline holds 31 molecules, with two assets in the pre-registration stage, four assets in Phase III development, and another six in Phase II.
  • Over the past decade, 174 clinical trials have been conducted in RVO. The year with the most studies initiated was 2015, with 23 trials, followed by 2016 with 22 trials.
  • During the past 16 months, eight mergers and acquisitions and 12 strategic alliances involving companies developing RVO assets were completed globally.
  • There is a significant unmet need for long-acting disease-modifying therapies that can reduce injection frequency while maintaining or improving efficacy and address the underlying pathophysiology of vein occlusion
Scope

GlobalData’s Retinal Vein Occlusion: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Retinal Vein Occlusion Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Retinal Vein Occlusion Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

114 Pages
    • KOL Insights
    • Disease Etiology
    • KOL insights - Disease Etiology and Pathophysiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of BRVO in 2024 and 2029
    • Epidemiology Overview - Diagnosed Prevalent Cases of CRVO in 2024 and 2029
    • KOL insights - Patient Population
    • Treatment Algorithm for Management of RVO
    • KOL Insights - Treatment Guidelines
    • KOL Insights - Diagnosis and Treatment Management
    • Marketed Drugs - Leading Marketed Drugs in RVO
    • KOL Insights - Marketed Products
    • Marketed Drugs - Overview of Drugs by Approval and Drug Type
    • Marketed Drugs - Overview by MOA
    • Marketed Drugs - Overview by Molecule type
    • Marketed Drug Profile - Roche's Vabysmo
    • Marketed Drug Profile - AbbVie's Ozurdex
    • Marketed Drug Profile - Wakamoto Pharmaceutical's Maqaid
    • KOL Insights - Unmet Needs in RVO
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Ozurdex
    • Marketed Drugs - Time to Pricing and Reimbursement for Vabysmo
    • KOL insights - Pricing and Reimbursement
    • Pipeline Drugs Overview - Mid- to Late-Stage Pipeline Drugs in RVO
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by MOA
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drug Profile - Xbrane Biopharma's Ranibizumab Biosimilar - Sales Forecast
    • Pipeline Drug Profile - Xbrane Biopharma's Ranibizumab Biosimilar - Summary
    • Pipeline Drug Profile - Shandong Boan Biotechnology's Aflibercept Biosimilar
    • Pipeline Drug Profile - Alvotech's Aflibercept Biosimilar
    • Pipeline Drug Profile - Roche's Faricimab - Sales Forecast
    • Pipeline Drug Profile - Roche's Faricimab - Summary
    • Pipeline Drug Profile - Kodiak Science's Tarcocimab Tedromer - Sales Forecast
    • Pipeline Drug Profile - Kodiak Science's Tarcocimab Tedromer - Summary
    • Pipeline Drug Profile - Outlook Therapeutics' Bevacizumab - Sales Forecast
    • Pipeline Drug Profile - Outlook Therapeutics' Bevacizumab - Summary
    • Pipeline Drug Profile - Sunshine Guojian Pharmaceutical's 601A anti-VEGF mAb
    • Pipeline Drug Profile - Sunshine Guojian Pharmaceutical's 601A anti-VEGF Ab - Summary
    • Pipeline Drugs - PTSR and LoA in Ophthalmology Disorders & RVO
    • Pipeline Drugs - PTSR and LoA in RVO
    • KOL Insights - Pipeline Drugs
    • KOL Insights - Clinical Trials
    • Clinical Trials in RVO - Historical Overview by Phase
    • Clinical Trials in RVO - Historical Overview by Sponsor Type
    • Clinical Trials in RVO - Overview by Phase
    • Clinical Trials in RVO - Overview by Status
    • Clinical Trials in RVO - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in RVO - Trials with a Virtual Component
    • Clinical Trials in RVO - Top 20 Biomarkers by Trial Phase
    • Clinical Trials in RVO - Geographic Overview
    • Clinical Trials in RVO - Single-Country and Multinational Trials by Region
    • Clinical Trials in RVO - Top Sponsors with Breakdown by Phase
    • Clinical Trials in RVO - Top Sponsors with Breakdown by Status
    • Clinical Trials in RVO - Overview by Endpoint Status
    • Clinical Trials in RVO - Overview by Race and Ethnicity of Trial Participants
    • Clinical Trials in RVO - Enrollment Data
    • Clinical Trials in RVO - Overview of Sites by Geography
    • Clinical Trials in RVO - Top 20 Countries for Trial Sites
    • Clinical Trials in RVO - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for RVO
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in RVO by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in RVO
    • Commercial Assessment - Key Market Players in RVO
    • Future Market Catalysts - Upcoming Market Catalysts in RVO
    • Primary Research: KOL Information
    • Methodology - Sales Forecasts
    • Methodology
    • Methodology - Pricing and Reimbursement
    • Methodology - PTSR and LoA Analysis
    • About the Authors

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us